Hanmi Science Co., Ltd. (KRX:008930)
South Korea · Delayed Price · Currency is KRW 38,550
+550 (1.45%)
Apr 8, 2026, 3:30 PM KST
Hanmi Science Revenue
In the year 2025, Hanmi Science had annual revenue of 1.36T KRW with 5.73% growth. Hanmi Science had revenue of 285.67B in the quarter ending December 31, 2025, with 5.17% growth.
Revenue
1.36T
Revenue Growth
+5.73%
P/S Ratio
1.92
Revenue / Employee
2.85B
Employees
476
Market Cap
2.61T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.36T | 73.53B | 5.73% |
| Dec 31, 2024 | 1.28T | 35.53B | 2.85% |
| Dec 31, 2023 | 1.25T | 201.85B | 19.30% |
| Dec 31, 2022 | 1.05T | 95.89B | 10.09% |
| Dec 31, 2021 | 950.16B | 92.78B | 10.82% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| PharmaResearch | 536.29B |
| Hugel | 425.11B |
| ST Pharm | 331.68B |
| Celltrion Pharm | 274.73B |
| Sam Chun Dang Pharm. | 231.81B |
| ALTEOGEN | 215.86B |